Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2025 08:00 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

GAL-101 well tolerated; excellent safety and pharmacokinetic profile strongly supports oral administrationNext arms of study, including multiple ascending dose (MAD), underway and expected to complete...
June 03, 2024 00:00 ET | Source: Biophta

BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique

COMMUNIQUÉ DE PRESSE BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique Ce tour de table a été réalisé par UI Investissement (via le...
June 03, 2024 00:00 ET | Source: Biophta

BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage

PRESS RELEASE BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage The seed round was co-led by UI Investissement (via the...
March 29, 2023 08:00 ET | Source: Galimedix Therapeutics, Inc.

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need

Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net salesEquity investment by Théa Open Innovation into Galimedix supports further...